NCT00000889View on ClinicalTrials.gov

A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 1997

Primary Completion Date

December 31, 1999

Study Completion Date

December 31, 1999

Conditions
HIV Infections
Interventions
DRUG

Aldesleukin

Trial Locations (4)

Unknown

Hospital de Clinicas 'Jose de San Martin' C601-040 CRS, Ciudad de Buenos Aires

Hospital F.J. Muniz C601-050 CRS, Ciudad de Buenos Aires

Hospital General de Agudos J.M. Ramos Mejia CPCRA CRS, Ciudad de Buenos Aires

Hospital Italiano de Buenos Aires C601-020 CRS, Ciudad de Buenos Aires

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000889 - A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 | Biotech Hunter | Biotech Hunter